Keith Gottesdiener, MD, is Chief Executive Officer of Rhythm Pharmaceuticals, Inc., a Boston-based biotech company that specializes in the development of peptide therapeutics for the treatment of metabolic diseases. Dr. Gottesdiener brings great depth and breadth of experience in pharmaceutical development. Previously, he spent 16 years at Merck Research Laboratories, first leading early clinical development at Merck, then leading all late-stage clinical development efforts. Overall, he played a leading role or was directly responsible for the US approval of more than10 new drug applications and the successful submission of more than 200 investigational new drug applications.
Dr. Gottesdiener received his BA from Harvard College and his MD from the University of Pennsylvania. He completed his residency in internal medicine and an infectious disease fellowship at the Brigham and Women’s Hospital of Harvard Medical School.
His bibliography includes more than 140 peer-reviewed published articles.
Study to Evaluate RM-131 Administered to Parkinson’s Patients with Chronic Constipation